Kenvue Inc. Common Stock vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.34 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 9.5× Kenvue Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals.
| KVUE | VEA | |
|---|---|---|
Market Cap | $34.06B | $323.80B |
Volume | 23,267,228 | 17,001,112 |
Sector | Consumer Staples | — |
52-Week High | $19.83 | $73.79 |
52-Week Low | $14.11 | $58.90 |
Enterprise Value | $41.56B | — |
Dividend Yield | 4.74% | — |
Typical Hold Time | — | 131 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VEA trades at $70.35 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with strong sell signals from moving averages and oscillators, though RSI suggests potential oversold conditions. The ETF maintains competitive advantages with a low 0.03% expense ratio and higher dividend yield compared to peers. Recent institutional activity shows mixed sentiment with both significant position increases and reductions among major holders.
VEA offers cost-efficient exposure to developed international markets excluding the US, but faces headwinds from global market volatility. The bearish technical setup and mixed institutional positioning suggest cautious near-term outlook, though the fund's structural advantages provide long-term appeal for diversified international exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →